1. Single nucleotide polymorphism (SNPs) are responsible for
r. r. r. r. r. r.
r . interpersonal variability in drug response r. r. r. r. r.
r. lack of effectiveness in certain individuals
r. r. r. r. r.
r . adverse drug reactions in certain individuals r. r. r. r. r.
r . All of the above
r. r. r.
2. Cytochrome P450 enzymes r. r.
r. Catalyse the general reaction: RH + O2 + FADH2 ROH + FAD + H2O r. r. r. r. r. r. r. r. r. r. r. r. r. r.
r. Are always associated with liver mitochondria
r. r. r. r. r.
r . Contain a copper moiety as part of their active site r. r. r. r. r. r. r. r. r. r.
r. Are dioxygenases r.
r . Catalyse reactions which convert lipid soluble xenobiotics to more r. r. r. r. r. r. r. r.
r. water soluble metabolites r. r.
3. Describe the primary purpose of Phase II metabolism in the context of
r. r. r. r. r. r. r. r. r. r. r.
xenobiotic processing.
r. r.
r . Phase II metabolism aims to produce reactive intermediates for
r. r. r. r. r. r. r. r.
further reactions.
r. r.
r. Phase II metabolism is responsible for the initial activation of
r. r. r. r. r. r. r. r. r.
xenobiotics.
r.
r. Phase II metabolism focuses on the detoxification of lipophilic
r. r. r. r. r. r. r. r.
compounds without modifying their structure.
r. r. r. r. r.
r. The primary purpose of Phase II metabolism is to increase the water
r. r. r. r. r. r. r. r. r. r. r.
solubility of modified compounds for excretion.
r. r. r. r. r. r.
,4. What are some examples of factors that can induce Cytochrome P450
r. r. r. r. r. r. r. r. r. r.
enzyme expression?
r . r.
r . Environmental chemicals and pharmaceuticals r. r. r.
r . Physical exercise and hydration r. r. r.
r . Genetic mutations and dietary changesr. r. r. r.
r. Hormonal fluctuations and aging
r. r. r. r.
5. What are some examples of factors that can induce CYP expression?
r. r. r. r. r. r. r. r. r. r.
r . Viral infections and bacterial exposure
r. r. r. r.
r . Smoking, alcohol consumption, and certain medications
r. r. r. r. r.
r . Dietary changes and exercise r. r. r.
r . Genetic mutations and environmental toxins
r. r. r. r.
6. The most important mixed-function oxidase in the liver responsible for
r. r. r. r. r. r. r. r. r.
metabolizing drugs is:
r. r. r.
r. N-
acetylase. r.
r. Hydrolase.
r. Peptidase.
r . Cytochrome P-450 isozymes (CYP450). r. r. r.
7. What is the primary function of Cytochrome P450 enzymes in Phase 1 drug
r. r. r. r. r. r. r. r. r. r. r. r.
metabolism?
r.
r . Convert drugs into water-soluble forms for easy excretion
r. r. r. r. r. r. r. r.
Convert drugs into lipophilic forms for storage in fat cells
r. r. r. r. r. r. r. r. r. r.
, r. Introduce functional groups onto drug molecules to prepare them
r. r. r. r. r. r. r. r.
for Phase 2 reactions
r. r. r. r.
r . Increase the toxicity of drugs r. r. r. r.
8. Which enzymes are primarily responsible for Phase I metabolism in
r. r. r. r. r. r. r. r. r.
xenobiotic processing?
r. r.
r . Glutathione S-transferases r.
r . UDP-glucuronosyltransferases
r. Cytochrome P450 enzymes r. r.
r . Alcohol dehydrogenases r.
9. Phase I and Phase II metabolism:
r. r. r. r. r.
r. Tend to make xenobiotic compounds more lipophilic.
r. r. r. r. r. r. r.
r. Always result in highly toxic products. r. r. r. r. r.
r . Utilizes enzymes that are very specific to the individual chemical
r. r. r. r. r. r. r. r. r.
r . Are used to detoxify and eliminate xenobiotic compounds
r. r. r. r. r. r. r.
10. If a population has a high prevalence of a specific SNP that decreases CYP
r. r. r. r. r. r. r. r. r. r. r. r. r.
enzyme activity, what might be the implications for drug metabolism and
r. r. r. r. r. r. r. r. r. r. r.
toxicity in that population?
r. r. r. r.
r . The population will have no change in drug metabolism or toxicity.
r. r. r. r. r. r. r. r. r. r.
r. The population may experience slower drug metabolism and
r. r. r. r. r. r. r.
r.increased toxicity. r.
r. The population will metabolize drugs faster and experience less
r. r. r. r. r. r. r. r.
r.toxicity.
r. The population will metabolize drugs normally but with increased
r. r. r. r. r. r. r. r.
r.efficacy.
, 11. What are the three potential adverse health outcomes mentioned in relation
r. r. r. r. r. r. r. r. r. r.
to xenobiotic metabolism?
r . r. r.
r . Allergic reactions, inflammation, and improved detoxification
r. r. r. r. r.
r . Increased energy production, DNA repair, and enhanced immunity r. r. r. r. r. r. r.
r . Toxicity, DNA damage, and an increased risk of cancer
r. r. r. r. r. r. r. r.
r . Weight gain, increased metabolism, and improved digestion
r. r. r. r. r. r.
12. If a new drug is found to be metabolized primarily by Cytochrome P450
r. r. r. r. r. r. r. r. r. r. r. r.
enzymes, what implications might this have for patient safety?
r. r. r. r. r. r. r. r. r.
r . Potential for drug interactions and variability in metabolism due to
r. r. r. r. r. r. r. r. r.
r. genetic differences. r.
r . Decreased need for monitoring drug levels in patients. r. r. r. r. r. r. r. r.
r. Increased efficacy of the drug without any risks. r. r. r. r. r. r. r.
r . No implications, as all drugs are metabolized the same way.
r. r. r. r. r. r. r. r. r.
13. If a new drug is designed to enhance Phase II metabolism, what would be
r. r. r. r. r. r. r. r. r. r. r. r. r.
the expected outcome on the drug's excretion and potential toxicity?
r. r. r. r. r. r. r. r. r. r.
r . Decreased excretion and increased potential toxicity r. r. r. r. r.
r . Increased excretion and reduced potential toxicity r. r. r. r. r.
r . Decreased excretion and reduced potential toxicity r. r. r. r. r.
r . No change in excretion and increased potential toxicity
r. r. r. r. r. r. r.
14. If a new drug is designed to be highly lipophilic, what metabolic phase
r. r. r. r. r. r. r. r. r. r. r. r.
would be crucial for its elimination from the body, and why?
r. r. r. r. r. r. r. r. r. r. r.
r. Phase I metabolism is crucial for its elimination as it functionalizes
r. r. r. r. r. r. r. r. r. r.
the drug to increase its water solubility.
r. r. r. r. r. r. r.
r. r. r. r. r. r.
r . interpersonal variability in drug response r. r. r. r. r.
r. lack of effectiveness in certain individuals
r. r. r. r. r.
r . adverse drug reactions in certain individuals r. r. r. r. r.
r . All of the above
r. r. r.
2. Cytochrome P450 enzymes r. r.
r. Catalyse the general reaction: RH + O2 + FADH2 ROH + FAD + H2O r. r. r. r. r. r. r. r. r. r. r. r. r. r.
r. Are always associated with liver mitochondria
r. r. r. r. r.
r . Contain a copper moiety as part of their active site r. r. r. r. r. r. r. r. r. r.
r. Are dioxygenases r.
r . Catalyse reactions which convert lipid soluble xenobiotics to more r. r. r. r. r. r. r. r.
r. water soluble metabolites r. r.
3. Describe the primary purpose of Phase II metabolism in the context of
r. r. r. r. r. r. r. r. r. r. r.
xenobiotic processing.
r. r.
r . Phase II metabolism aims to produce reactive intermediates for
r. r. r. r. r. r. r. r.
further reactions.
r. r.
r. Phase II metabolism is responsible for the initial activation of
r. r. r. r. r. r. r. r. r.
xenobiotics.
r.
r. Phase II metabolism focuses on the detoxification of lipophilic
r. r. r. r. r. r. r. r.
compounds without modifying their structure.
r. r. r. r. r.
r. The primary purpose of Phase II metabolism is to increase the water
r. r. r. r. r. r. r. r. r. r. r.
solubility of modified compounds for excretion.
r. r. r. r. r. r.
,4. What are some examples of factors that can induce Cytochrome P450
r. r. r. r. r. r. r. r. r. r.
enzyme expression?
r . r.
r . Environmental chemicals and pharmaceuticals r. r. r.
r . Physical exercise and hydration r. r. r.
r . Genetic mutations and dietary changesr. r. r. r.
r. Hormonal fluctuations and aging
r. r. r. r.
5. What are some examples of factors that can induce CYP expression?
r. r. r. r. r. r. r. r. r. r.
r . Viral infections and bacterial exposure
r. r. r. r.
r . Smoking, alcohol consumption, and certain medications
r. r. r. r. r.
r . Dietary changes and exercise r. r. r.
r . Genetic mutations and environmental toxins
r. r. r. r.
6. The most important mixed-function oxidase in the liver responsible for
r. r. r. r. r. r. r. r. r.
metabolizing drugs is:
r. r. r.
r. N-
acetylase. r.
r. Hydrolase.
r. Peptidase.
r . Cytochrome P-450 isozymes (CYP450). r. r. r.
7. What is the primary function of Cytochrome P450 enzymes in Phase 1 drug
r. r. r. r. r. r. r. r. r. r. r. r.
metabolism?
r.
r . Convert drugs into water-soluble forms for easy excretion
r. r. r. r. r. r. r. r.
Convert drugs into lipophilic forms for storage in fat cells
r. r. r. r. r. r. r. r. r. r.
, r. Introduce functional groups onto drug molecules to prepare them
r. r. r. r. r. r. r. r.
for Phase 2 reactions
r. r. r. r.
r . Increase the toxicity of drugs r. r. r. r.
8. Which enzymes are primarily responsible for Phase I metabolism in
r. r. r. r. r. r. r. r. r.
xenobiotic processing?
r. r.
r . Glutathione S-transferases r.
r . UDP-glucuronosyltransferases
r. Cytochrome P450 enzymes r. r.
r . Alcohol dehydrogenases r.
9. Phase I and Phase II metabolism:
r. r. r. r. r.
r. Tend to make xenobiotic compounds more lipophilic.
r. r. r. r. r. r. r.
r. Always result in highly toxic products. r. r. r. r. r.
r . Utilizes enzymes that are very specific to the individual chemical
r. r. r. r. r. r. r. r. r.
r . Are used to detoxify and eliminate xenobiotic compounds
r. r. r. r. r. r. r.
10. If a population has a high prevalence of a specific SNP that decreases CYP
r. r. r. r. r. r. r. r. r. r. r. r. r.
enzyme activity, what might be the implications for drug metabolism and
r. r. r. r. r. r. r. r. r. r. r.
toxicity in that population?
r. r. r. r.
r . The population will have no change in drug metabolism or toxicity.
r. r. r. r. r. r. r. r. r. r.
r. The population may experience slower drug metabolism and
r. r. r. r. r. r. r.
r.increased toxicity. r.
r. The population will metabolize drugs faster and experience less
r. r. r. r. r. r. r. r.
r.toxicity.
r. The population will metabolize drugs normally but with increased
r. r. r. r. r. r. r. r.
r.efficacy.
, 11. What are the three potential adverse health outcomes mentioned in relation
r. r. r. r. r. r. r. r. r. r.
to xenobiotic metabolism?
r . r. r.
r . Allergic reactions, inflammation, and improved detoxification
r. r. r. r. r.
r . Increased energy production, DNA repair, and enhanced immunity r. r. r. r. r. r. r.
r . Toxicity, DNA damage, and an increased risk of cancer
r. r. r. r. r. r. r. r.
r . Weight gain, increased metabolism, and improved digestion
r. r. r. r. r. r.
12. If a new drug is found to be metabolized primarily by Cytochrome P450
r. r. r. r. r. r. r. r. r. r. r. r.
enzymes, what implications might this have for patient safety?
r. r. r. r. r. r. r. r. r.
r . Potential for drug interactions and variability in metabolism due to
r. r. r. r. r. r. r. r. r.
r. genetic differences. r.
r . Decreased need for monitoring drug levels in patients. r. r. r. r. r. r. r. r.
r. Increased efficacy of the drug without any risks. r. r. r. r. r. r. r.
r . No implications, as all drugs are metabolized the same way.
r. r. r. r. r. r. r. r. r.
13. If a new drug is designed to enhance Phase II metabolism, what would be
r. r. r. r. r. r. r. r. r. r. r. r. r.
the expected outcome on the drug's excretion and potential toxicity?
r. r. r. r. r. r. r. r. r. r.
r . Decreased excretion and increased potential toxicity r. r. r. r. r.
r . Increased excretion and reduced potential toxicity r. r. r. r. r.
r . Decreased excretion and reduced potential toxicity r. r. r. r. r.
r . No change in excretion and increased potential toxicity
r. r. r. r. r. r. r.
14. If a new drug is designed to be highly lipophilic, what metabolic phase
r. r. r. r. r. r. r. r. r. r. r. r.
would be crucial for its elimination from the body, and why?
r. r. r. r. r. r. r. r. r. r. r.
r. Phase I metabolism is crucial for its elimination as it functionalizes
r. r. r. r. r. r. r. r. r. r.
the drug to increase its water solubility.
r. r. r. r. r. r. r.
